Sandra M J De Meyer - Infectious Diseases

Author Information

Sandra M J De Meyer is a researcher affiliated with Janssen Infectious Diseases BVBA, located in Beerse, Belgium. Her work predominantly revolves around infectious diseases, with a particular focus on virology and therapeutic interventions against viruses such as SARS-CoV-2 and HIV.

Research Contributions

Sandra M J De Meyer has made significant contributions to the field of infectious diseases, particularly through her research on antiviral therapies. Her work includes the development and optimization of high-throughput screening assays for in vitro anti-SARS-CoV-2 activity, as well as studies on the activity of itraconazole and darunavir against SARS-CoV-2. Additionally, she has conducted extensive research on HIV treatment regimens, including the analysis of resistance to various antiviral drugs. Her studies are crucial for understanding and improving therapeutic strategies against these viruses.

Aliases

Sandra M J De Meyer is also referred to by several aliases, including S De Meyer, S. De Meyer, and Sandra De Meyer. These variations may appear across different publications and databases.

Publication and Citation Metrics

Metric	Value
Total Citation Count	4717
h-index	29
Total Number of Papers	70

Publications:

Real-world monitoring of BNT162b2 vaccine-induced SARS-CoV-2 B and T cell immunity in naive healthcare workers: a prospective single center study

DOI: 10.1101/2022.01.17.22269081

Year: 2022

Development and optimisation of a high-throughput screening assay for in vitro anti–SARS-CoV-2 activity: evaluation of 5676 phase 1 passed structures

DOI: 10.1101/2022.02.02.478671

Year: 2022

Development and optimisation of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity: evaluation of 5676 phase 1 passed structures.

DOI: 10.1002/jmv.27683

Year: 2022

In vitro activity of itraconazole against SARS‐CoV‐2

DOI: 10.1002/jmv.26917

Year: 2021

In Vitro Activity of Itraconazole Against SARS-CoV-2

DOI: 10.1101/2020.11.13.381194

Year: 2020

Pooled resistance analyses of darunavir once-daily regimens and formulations across 10 clinical studies of treatment-naïve and treatment-experienced patients with human immunodeficiency virus-1 infection

DOI: 10.1080/25787489.2020.1794439

Year: 2020

Virology analysis of chronic hepatitis B virus–infected patients treated for 28 days with JNJ‐56136379 monotherapy

DOI: 10.1111/jvh.13351

Year: 2020

Lack of Antiviral Activity of Darunavir against SARS-CoV-2

DOI: 10.1101/2020.04.03.20052548

Year: 2020

Lack of antiviral activity of darunavir against SARS-CoV-2

DOI: 10.1016/j.ijid.2020.05.085

Year: 2020

Week 96 resistance analyses of the once‐daily, single‐tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV‐1 from the phase 3 randomized AMBER and EMERALD trials

DOI: 10.1002/jmv.26721

Year: 2020

What Are the Challenges in Targeting Glycolysis?

What are the Future Directions in Parasite DNA Research?

How Effective are Vaccines?

What is Bovine Tuberculosis?

How Do Decongestants Work?

How does it spread?

What are Histone Deacetylase Inhibitors?

What are the Key Components of Infectious Disease Education?

Why are Drug Targets Important?

Is There a Vaccine for E. Coli?

Partnered Content Networks

Relevant Topics